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ABSTRACT
A major challenge of the post-genomic era is the
functional characterization of anonymous open read-
ing frames (ORFs) identified by the Human Genome
Project. In this context, there is a strong requirement
forthedevelopmentoftechnologiesthatenhanceour
ability to analyze gene functions at the level of the
whole organism. Here, we describe a rapid and effici-
ent procedure to generate transgenic chimaeric mice
that continuously secrete a foreign protein into the
systemic circulation. The transgene units were inser-
ted into the genomic site adjacent to the endogenous
immunoglobulin(Ig) klocus by homologous recomb-
ination,usingamodifiedmouseembryonicstem(ES)
celllinethatexhibitsahighfrequencyofhomologous
recombination at the Igk region. The resultant
ES clones were injected into embryos derived from
a B-cell-deficient host strain, thus producing
chimaerism-independent, B-cell-specific transgene
expression. This feature of the system eliminates
the time-consuming breeding typically implemented
instandardtransgenicstrategiesandallowsforevalu-
ating the effect of ectopic transgene expression dir-
ectly in the resulting chimaeric mice. To demonstrate
the utility of this system we showed high-level pro-
tein expression in the sera and severe phenotypes
in human EPO (hEPO) and murine thrombopoietin
(mTPO) transgenic chimaeras.
INTRODUCTION
The completion of human genome sequencing (1) has identi-
ﬁedthousandsofopenreading frames(ORFs)thathave notyet
been assigned signiﬁcant annotation. Exploring the functions
of each of these ORFs is clearly an important step in biomed-
ical research, and may lead to the development of novel phar-
maceuticals and strategies to treat human diseases. In this
context, much effort has been made to develop methodologies
that can deﬁne gene functions in a variety of model organisms,
thereby determining whether the candidate gene is ‘drugable’
or not. Secreted protein-coding ORFs, which are estimated to
account for about one-ﬁfth of all human protein-coding genes
(2,3), bear particular attention in this regard since many of the
mostimportant biotherapeutics have resulted fromthe applica-
tion of secreted proteins, including hormones, growth factors
and cytokines. These can also be developed as potential targets
for small molecule and antibody therapeutics.
Among various approaches for deﬁning orphan gene func-
tion, transgenics and knockouts have been recognized as direct
means for elucidating in vivo gene functions and have been
widelyemployed(4). Generatinganoverexpressingtransgenic
by pronuclear injection can be informative; Simonet et al. (5)
generated transgenic mice that expressed cDNAs from a liver-
speciﬁc apolipoprotein E (ApoE) gene promoter. This study
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doi:10.1093/nar/gni083identiﬁed a novel protein, osteoprotegerin (OPG), whose
expression led to a signiﬁcant increase in bone mass in the
resulting transgenic mice. Erythropoietin (EPO) is another
example of a protein that, when overexpressed in the
mouse, results in a phenotype that mimics the action of a
therapeutic protein in humans (6).
The standard methods used to produce transgenic mice are
inherently expensive and low throughput. Random integration
ofatransgeneintoanundeﬁnedregionofthehostgenomeoften
causes difﬁculty in obtaining lines with the intended transgene
expression. Embryonic lethality caused by transgene expres-
sion is a common impediment to the functional assessment of
therapeutic candidates. Single-copy transgenic mice (7), gen-
eratedfromembryonicstem(ES)cellscarryingatargetedinteg-
ration of transgene into a predetermined genomic site, could
confer more controlled expression. However, both labor-
intensive homologous recombination in ES cells and low efﬁ-
cienciesinobtaininggermlinetransmissionhavehamperedthe
application of this strategy to large-scale screening.
Wedescribehereanovelapproachthatenablestherapidand
efﬁcient evaluation of the in vivo functions of ORFs encoding
secreted proteins. Candidate cDNAs ﬂanked by immuno-
globulin kappa (Igk) light-chain gene promoter are integrated
into a site adjacent to the endogenous Igk gene by homologous
recombination, thus directing the transgene expression to
circulating B-lymphocytes. The use of a modiﬁed ES cell line
exhibiting improved rates of homologous recombination at the
Igk locus facilitates the production of an ES line carrying a
targeted transgene. Large numbers of chimaeras that show a
uniform level of transgene expression without chimaerism
dependency can be readily produced by blastocyst comple-
mentation using B-cell-deﬁcient host embryos. Phenotypic
assessmentscanbeperformedimmediatelyintheresultantchi-
maeras, thus eliminating the need to establish germline trans-
mission of the transgene. To demonstrate the utility of this
system we showed high-level protein expression in the sera
and severe phenotypes in human EPO (hEPO) and murine
thrombopoietin (mTPO) transgenic chimaeras.
MATERIALS AND METHODS
Generation of DRS-ES cell line
A C57BL/6 strain-derived bacterial artiﬁcial chromosome
(BAC, RP23-435I4) including the recombining sequence (RS)
wasusedforthePCRampliﬁcationof50 (5.2kb)and30 (2.2kb)
homologousarmstoconstructatargetingvector forgenerating
the DRS-ES cell line. Both PCR products were subcloned into
pBluescriptIIKS(-)vectorcontainingtheDT-Acassette(8)asa
negative selection marker, and subsequently the RS was repla-
cedbypSTneoB(9)(RS-KOvector).LinearizedRS-KOvector
was electroporated to TT2F ES cells (39,XO) (9) and the res-
ultantG418-resistantcloneswereanalyzedbySouthernblotting
toidentifyhomologousrecombinants.Detailsofthegeneration
of DRS-ES cell lines will be described elsewhere (M. Kakitani
and K. Tomizuka, manuscript in preparation).
Targeting vector construction
A C57BL/6 strain-derived genomic DNA fragment (13.5 kb,
EcoRI–XhoI) including the Jk–Ck region and the DT-A
cassette (8) for negative selection were subcloned into pBlue-
script II KS (-) vector (pIgkDTA). The Igk expression unit for
introducing the exogenous cDNA was constructed as follows.
The 0.21 kb Vk promoter fragment (VkP) and 0.31 kb frag-
ment (CkpA) including the Ck polyA site were ampliﬁed by
PCR using C57BL/6 mouse genomic DNA as a template and
the following primer pairs: VkP-forward, CCCAAGCTTTG-
GTGATTATTCAGAGTAGTTTTAGATGAGTGCAT; VkP-
reverse, ACGCGTCGACTTTGTCTTTGAACTTTGGTCC-
CTAGCTAATTACTA; CkpA-forward, ACGCGTCGACG-
CGGCCGGCCGCGCTAGCAGACAAAGGTCCTGAGACG-
CCACCACCAGCTCCC (including SalI, NaeI, FseI and NheI
sites at the 50 end); CkpA-reverse, GAAGATCTCAAGT-
GCAAAGACTCACTTTATTGAATATTTTCTG (including
the BglII site at the 50 end). The VkP and CkpA fragments
were subcloned and the multi cloning site (MCS: SalI–NaeI–
FseI–NheI) for cDNA insertion was artiﬁcially generated
between these two fragments. The VkP–MCS–CkpA unit
(Igk expression unit) and puro
r marker cassette (2.4 kb,
pPGKpuro) (9) were inserted into the site 0.25 kb downstream
from the native Ck polyA site on the pIgkDTA vector (pKI-
univ). The orientation for transcription of the Igk expression
unit and puro
r cassette is the same as that of endogenous Igk
gene.
The following primer pair was used for ampliﬁcation of a
human EPO cDNA fragment from human kidney ﬁrst-strand
cDNA (Stratagene): hEPO, forward, CCGCTCGAGCGGC-
CACCATGGGGGTGCACGAATGTCCTG (including the
XhoI site and Kozak sequence at the 50 end) and
reverse,CCGCTCGAGCGGTCATCTGTCCCCTGTCCTGCA
(including the XhoI site at the 50 end). The XhoI-digested PCR
product was inserted into the SalI site within the MCS of the
pKIuniv vector. A cDNA fragment of murine TPO was also
prepared from mouse liver ﬁrst-strand cDNA (Stratagene) by
using a following primer pair and subsequently inserted into
the SalI–FseI site of the pKIuniv vector: mTPO, forward,
CCGCTCGAGCGGCCACCATGGAGCTGACTGATTTGC-
TCCTG (including the XhoI site and Kozak sequence at the 50
end) and reverse, CCGGCCGGCCGCAAATCTATGTTT-
CCTGAGACAAATTCCTGGG (including the Fse I site at
the 50 end). Targeting vectors containing the other transgenes
were also constructed as described above and details will be
given elsewhere (M. Kakitani and K. Tomizuka, manuscript in
preparation).
Generation of targeted ES cells
NotI-digested, linearized targeting vector was transferred by
electroporation into wild-type (WT)-ES or DRS-ES cells.
Genomic DNA samples prepared from puromycin-resistant
ES clones were analyzed by Southern blotting to identify
homologous recombinants. ES clones with normal karyotype
were selected for subsequent chimaera production.
Chimaera production
The targeted ES cells were injected into eight-cell to morula
stage embryos prepared from the immunoglobulin m heavy-
chain-KO (Dm) homozygous mouse strain (9). After develop-
ment of embryos to blastocysts, approximately 10 injected
embryos were transplanted into a pseudopregnant MCH(ICR)
mouse (Clea Japan, Inc.). Chimaerism in the offspring was
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(dark brown) in the host embryo MCH(ICR)-derived albino
coat color (white). Mice were kept under a 12/12-h dark/light
cycle (lights on at 8:00 a.m.) and received 5 mm ﬁltered water
and CE-2 food (Clea Japan, Inc.) ad libitum. Male mice were
housed individually after weaning.
Expression analysis of transgenes
First-strand cDNA was synthesized with Superscript III (Invit-
rogen) using random hexamers and 250 ng of total RNA
extracted from 4-week-old hEPO/DRS and DRS control chi-
maeric tissues. Semi-quantitative RT–PCR analysis was car-
ried out using the cDNA at speciﬁc annealing temperatures for
each primer pair. PCR products were electrophoresed on 2%
agar gels and stained with ethidium bromide. The integrity of
RNA was controlled by the ampliﬁcation of cDNA generated
by the murine GAPDH. Primer pairs were hEPO-forward,
GGCCAGGCCCTGTTGGTCAACTCTTC; hEPO-reverse,
CGCTTGTGGGGAAGCCTCCAAGACC; Ck-forward,CAA-
CTGTATCCATCTTCCCACCATC; Ck-reverse, ATGTCG-
TTCATACTCGTCCTTGGTC; GAPDH-forward, CACCAT-
GGAGAAGGCCGGGGCCCAC; GAPDH-reverse, ATCAT-
ACTTGGCAGGTTTCTCCAGG.
Serum concentrations of mouse TPO and human EPO were
measured by ELISA (R & D Systems). Mouse Ig m (mm) and
g (mg) heavy chains were assayed as described previously (9).
Phenotypic analysis of transgenic chimaeras
AllprocedureswereapprovedbytheInstitutionalAnimalCare
and Use Committee at the Pharmaceutical Research Laborat-
ories, Kirin Brewery Co. Ltd. (Takasaki, Japan). Peripheral
blood samples used for measurement of B- and T-cell count,
ELISA for serum immunoglobulins, and blood cell analysis
(red blood cell, hemoglobin, platelet, reticulocyte, white blood
cell, lymphocyte, bosophil, eosinophil, neutrophil, monocyte,
large unstained cell, lobularity index) were obtained from
retro-orbital bleeds of chimaeric animals. Serum samples for
blood chemical analysis (albumin, total protein, alkali phos-
phatase,bloodureanitrogen,calcium,creatinenekinase,chlor-
ide, creatinine, total bilirubin, direct bilirubin, free cholesterol,
total cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, phospholipid, triglyceride,
non-esteriﬁed fatty acid, fructosamine, glycated albumin,
glucose, amylase, uric acid, total ketone body, glutamic oxalo-
acetic transaminase, glutamic pyruvic transaminase, inor-
ganic phosphorus, potassium, lactate dehydrogenase, leucine
aminopeptidase, magnesium, sodium, n-acetyl-beta-d-
glucosaminidase, iron and unsaturated iron-binding capacity)
werepreparedfromtheabdominalveinofsacriﬁcedchimaeras
and analyzed using a 7180 Automatic Analyzer (Hitachi High-
Technologies Corp., Tokyo, Japan). B- and T-cell counts of
mice in peripheral blood samples were measured by FACS
analysis. IgM and IgG concentration in serum samples were
measured by ELISA. An ADVIA 120 hematology system
(Bayer Medical Ltd.) was used for blood cell analysis. Chi-
maeric animals were sacriﬁced under ether anesthesia for
weight measurement and histological assessment of organs
(brain, heart, lung, thymus, mesenteric lymph nodes, femur,
ovary, testis, pancreas, liver, adrenal, kidney and spleen).
Hematoxylin-eosin staining was carried out for histological
analysis.
RESULTS
Generation of targeted ES clones
Our procedure is outlined in Figure 1. A targeting vector was
designed to optimize the expression of exogenous cDNAs in
B-lymphocytes (Figures 1 and 2A). The cDNA fragment has
been inserted into a cloning site within an expression unit
(Figures 1 and 2A) comprising the mouse Igk promoter
(0.21 kb) (10) and Ck polyA addition site (0.31 kb). This
expression unit is ﬂanked by a puro
r marker located at a down-
stream site of the Ck exon (Figure 2A). Targeted integration of
this expression unit by homologous recombination places the
expression of the transgene by the mouse Igk promoter; cis-
acting elements for this promoter include intronic and 30 Igk
enhancers (11,12). We constructed vectors encoding the
cDNA of human EPO (hEPO) and murine TPO (mTPO) as
modelgenes toevaluate the potential of this system since these
proteins have clear biological activities and have been used in
studies utilizing conventional trangenic techniques (6,13,14).
The recombining sequence (RS) is located 25 kb down-
stream of the Ck exon and undergoes V(D)J recombinase-
dependent rearrangement that inactivates the Igk locus by
deletional rearrangements in cis (15) (Figure 2A). Although
the involvement of RS rearrangements in receptor editing
during B-cell development has been suggested (16), the
functional signiﬁcance of this phenomenon remains unclear.
To examine the effects of deleting the RS on the expression of
Figure 1. Schematic diagram showing the generation of transgenic chimaeric
mice expressing secreted protein-coding ORFs in B-lymphocytes. The vector
construction, isolation of targeted ES clones and chimaera production usually
take 2, 3 and 3 weeks, respectively. Therefore, adult (4-week-old) chimaeras
can be obtained within 3 months from the starting point of vector construction.
The Igk expression unit is located at a site downstream of the C exon on the
targeting vector (see Figure 2A). The targeted ES clones were injected into
eight-cell to morula stage embryos prepared from a mouse strain homozygous
for Igkmheavy-chain-KO (Dm) (9), in which mature B-lymphocytes and
immunoglobulin production are absent. Igk-P: Igk promoter.
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whichRS was replaced with neomycin-resistant(Neo
r) marker
cassette (Figure 2A). We used a karyotypically normal DRS
line in addition to a WT-ES cell line to establish targeted ES
clones containing various cDNA fragments.
Targeting vectors containing the hEPO and mTPO cDNA
were transfected into both WT-ES (data not shown) and
DRS-ES (Figure 2B) cells and the resultant puro
r clones were
subjected to Southern analysis to identify homologous recom-
binants. In the WT-ES line studies, the ratio of homologous
recombinants to total puro
r clones (targeted/random: TR
ratio)was16%and3%inthehEPOandmTPOvectors,respect-
ively. Using the DRS-ES line, we observed a remarkable
increase in the TR ratio (hEPO: 65%, mTPO: 33%). Further
examinations using targeting vectors of 20 independent
cDNA fragments (0.5–1.6 kb) showed that the averaged TR
ratio is 15 times higher in the DRS-ES line (46%) than in the
WT-ES line (3%), indicating that the effect of the DRS-ES is
independentofthe sequenceofinsertedcDNA fragments (data
not shown) and is not the simple result of clonal variation.
Production of chimaeric mice
To circumvent the typical chimaerism-dependent variation
seen in the expression levels of transgenes, we utilized a
blastocyst complementation strategy that was developed
to evaluate gene function in lymphocytes (17). Injection
of normal ES cells into blastocysts from RAG-2 (recombina-
tion-activating gene 2) gene-deﬁcient blastocysts leads to
the generation of somatic chimaeras with mature B- and
T-cells, all of which derive from the injected ES cells
(17). In an analogous process intended to produce B-cell-
restricted expression, we used embryos prepared from
female mice with B-cell deﬁciency caused by the homozygous
deletion of the Ig m gene (Dm) (9). It should be noted
thatDmanimalshave noobviousdefectsotherthanthe absence
of mature B-lymphocytes and immunoglobulin production.
Eight-cell tomorulaDm(albino)embryoswere injected with
WT-ES and DRS-ES cells (agouti) and then implanted into
foster mothers. As with normal embryos,  20% of injected Dm
embryos were able to develop to viable chimaeras as judged
from coat colors. The B-cell population in peripheral blood
mononuclear cells of the resulting chimaeric pups was assayed
13 weeks after birth. Approximately 20–30% of the CD45-
positive cells were B220-positive in both WT-ES and DRS-ES
cell-derived chimaeric mice, a similar percentage to that seen
in normal MCH(ICR) mice (data not shown). Serum levels of
Igm and Igg in both types of chimaeras are comparable to those
in normal MCH(ICR) mice (data not shown), also demonstrat-
ing the reconstitution of mature B-cell populations derived
Figure 2. GenerationoftargetedEScelllines.(A)Targetingstrategy.(1)Wild-type(WT)endogenousIgk locus.Aclosedrectangleaboverepresentstheprobeused
inSouthernblotanalysis(P,1.28kbXhoI–EcoRIfragment).(2)DRSlocuswiththeG418-resistant(neo
r)cassettereplacingtheRSsiteoftheWTlocus.(3)Targeting
construct.TheIgk expressionunitflankedbya puromycin-resistant(puro
r) markerlocatesata downstream siteofthe Ck exon.50E,Igk intronicenhancer;30E, Igk
30-enhancer; DT-A, diphtheria toxin A-fragment gene; pBS, pBluescript. Restriction enzyme sites are as follows: E, EcoRI; N, NotI; X, XhoI. (B) Southern blot
analysisofgenomicEcoRI-digestedDNApreparedfromninerandomlyselectedpuro
rEScloneshybridizedtotheprobeshowedin(A).Lane1,DRS-EScells.Lane
2–10,puromycin-resistantDRS-ESclonesobtainedbytransfectionwithhEPOtargetingvector.Sizemarkers,restrictionfragmentsthatrepresentWTallele( 14kb)
and targeted allele ( 12 kb) are indicated.
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tion between coat color chimaerism and serum Igm and Igg
levels (data not shown). We did not observe an unusual rate of
physical abnormalities in the chimaeras derived from WT-ES
and DRS-ES cells, nor any apparent changes in blood cell
analysis, serum chemical analysis, urinalysis and tissue weight
measurement (data not shown). We obtained 17 and 47 chi-
maeras derived from mTPO/WT-ES and hEPO/DRS-ES lines,
respectively.
Expression of transgenes in chimaeric mice
Total RNA samples were prepared from various tissues of
4-week-old hEPO/DRS chimaeras and were subjected to
semi-quantitative RT–PCR analysis to examine tissue-
speciﬁcity of transgene expression (Figure 3). hEPO tran-
scripts were prominent in the spleen, thymus and bone
marrow, whereas a weak but detectable signal was observed
in lung and kidney sections. This expression pattern is con-
sistent with that of the Ck transcript (Figure 3) and represents
the distribution of B-lymphocytes in various adult tissues.
These results indicate that the Igk-driven transgene is properly
regulated and the transcript is predominantly detected in tis-
sues abundant in B-lymphocytes.
Serum protein levels produced from the transgenes were
also determined by enzyme-linked immunosorbent assays
(ELISAs) in hEPO/DRS and mTPO/WT chimaeras
(Figure 4A and B). The hEPO protein level was low but
detectable at 9 days of age and reached a plateau at
8 weeks (Figure 4A). A similar expression proﬁle was
observed for Igm protein (Figure 4A), also implying that the
major site of transgene expression is B-lymphocytes. In addi-
tion, the average serum concentration of hEPO protein in 6-
week-old hEPO/WT chimaeras (4.8 – 2.1 ng/ml, n = 6) was
comparable to that in hEPO/DRS chimaeras (4.3 – 1.3 ng/ml,
n = 47, Figure 4A), which indicates that the insertion of neo
r
marker cassette at the RS site did not signiﬁcantly affect the
transgene expression. In other studies, the levels of mTPO in
the sera of mTPO/WT chimaeras (4.3 – 1.6 ng/ml, n = 2)
were indistinguishable from those in a control WT chimaera
(4.5 ng/ml, n = 1) at 3 weeks of age (the ﬁrst time point
evaluated), whereas the increase became evident at 4 weeks
(11.1 – 3.5 ng/ml, n = 12). At 8 weeks, expression had
reached a plateau (36 – 20 ng/ml, n = 12, Figure 4B), nine
times higher than the level of the controls (4.1 – 1.5 ng/ml,
n = 4). Both hEPO and mTPO levels in all the tested
chimaeras persisted for at least 16 weeks. There was no
apparent correlation between coat color chimaerism and
Figure 3. TotalRNAsamplespreparedfrom10differenttissuesof4-week-old
hEPO/DRS and control DRS chimaeras were subjected to RT–PCR analysis
using hEPO (35 cycles) and Ck (35 cycles) specific primer pairs. The sizes of
resulting PCR products in all experiments were consistent with the expected
sizes predicted from reported cDNA sequences. Murine GAPDH (25 cycles)
was used as a control.
Figure 4. Serum expression of hEPO and mTPO in transgenic chimaeras. (A)
Time course of hEPO and Ig m levels in the sera of hEPO/DRS chimaeras. The
number of tested individuals at each time point is indicated below (n = 2–47).
Dataaremean(1-to16-week-old)andstandarddeviation(–SD,4-to16-week-
old). (B) Serum hEPO and mTPO protein levels in hEPO/DRS (n = 18) and
mTPO/WT (n = 12) chimaeras. Serum samples were prepared from 8-week-
oldanimalswitharangeofcoatcolorchimaerism.IntheseraofcontrolWTand
DRS chimaeras, the hEPO protein was not detectable (<0.1 ng/ml) and mTPO
level was 4.1 – 1.5 ng/ml (n = 4). No mTPO/WT chimaeras with 90–100%
chimaerism were examined.
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thus demonstrating the achievement of transgene exp-
ression that was independent of chimaerism by B-cell
complementation.
Phenotypic analysis of hEPO and mTPO
transgenic chimaeras
Severe erythrocytosis in hEPO/DRS chimaeras was evi-
denced by a signiﬁcant increase in red blood cell (RBC),
hematocrit (HCT) and reticulocyte (Retic) counts (Table 1).
We also observed a signiﬁcant decrease in platelet (PLT)
counts (Table 1). Visual inspection of hEPO/DRS mice at nec-
ropsy revealed an enlarged spleen, suggesting enhanced
extramedullar erythropoiesis. The wet weight of hEPO/DRS
chimaera spleens (0.98 – 0.62 g, n = 3, 16 weeks) was  10-
fold greater than that of the DRS controls (0.097 – 0.012 g,
n = 7, 16 weeks). Histological examination conﬁrmed
extramedullar erythropoiesis in the spleen (data not shown).
In addition, the life span was markedly reduced in hEPO/DRS
chimaeras; mean survival of hEPO/DRS chimaeras was 14
weeks (n = 27).
The mTPO/WT chimaeras exhibited thrombocytosis with a
5- to 8-fold increase in circulating PLT counts (Table 2). To
evaluate the effects of mTPO overexpression on other blood
cell parameters, we measured the levels of white blood cells
(WBC), neutrophil (NEUT), lymphocytes (LYM), monocytes
(MONO), eosinophils (EOS), basophils (BASO), RBC and
hematocrit HCT (Table 2). We observed >10-fold increases
in the circulating levels of myeloid and lymphoid cells, which
contrasted with a 30–40% decrease in the HCT and RBC.
Extramedullary hematopoiesis was observed in the liver, kid-
ney, lymph nodes and lung.
DISCUSSION
Secreted protein encoding sequences can be identiﬁed using
various bioinfomaticalgorithmsthatpredictthe presence ofN-
terminal secretory signal peptides (18,19). In addition, soluble
versions of single-pass membrane proteins can be produced
that lack trasmembrane and cytoplasmic domains, yet retain
their ability to bind cognate ligands. Both of these approaches
have found considerable success in developing candidate bio-
therapeutic proteins. Our system has been optimized for
screening large numbers of such cDNAs to ascertain their
role in physiological processes. The procedure is rapid, simple
andreproducible.Followingvector constructionbysingle-step
insertionofaPCR-ampliﬁedcodingsequence,we obtaindrug-
resistant ES cell transformants using standard electroporation
methods. The isolation and analysis of only 12 ES clones is
sufﬁcient to establish multiple ES lines carrying a transgene
insertion at the genomic site adjacent to the Igk gene. Sub-
sequently, large numbers of chimaeras can be produced by
injecting the resultant ES clones into B-cell-deﬁcient host
embryos. We have routinely produced >20 chimaeras in a
single-day injection (200 embryos) experiment. The primary
phenotypic assessments using adult (4-week-old) chimaeras
can be started within 3 months of the starting point of vector
construction (see Figure 1). Furthermore, in the case that
the transgene expression does not affect fertility in the chi-
maeras, germline transmission can be obtained for more
detailed studies.
The B-cell complementation strategy allows for the genera-
tion of high-expressing transgenic mice in a single step with-
out the requirement of time-consuming breeding techniques.
The data presented demonstrate that the chimaeras display
uniform transgene expression, irrespective of their coat
colorchimaerism;thusthefunctionalassessmentoftransgenes
Table 1. Erythropoietic parameters of non-transgenic DRS and hEPO/DRS chimaeras
DRS control hEPO/DRS
Female (n = 5) Male (n = 4) Female (n = 10) Male (n = 8)
RBC (·10
6 cells/mL) 10.8 – 0.32 10.2 – 0.71 19.1 – 1.48* 18.2 – 1.38*
HCT (%) 60.4 – 3.03 59.5 – 3.3 94.4 – 2.65* 94.6 – 2.56*
Retic (·10
3 cells/mL) 354 – 58 429 – 206 2674 – 373* 2248 – 304*
PLT (·10
3 cells/mL) 1290 – 201 1353 – 212 747 – 198* 621 – 241*
*P < 0.001.
Data are presented as mean values – SD for animals of 8 weeks of age.
Table 2. Hematologic analysis of non-transgenic WT and mTPO/WT chimaeras
WT control mTPO/WT
Female (n = 79) Male (n = 23) Female (n = 13) Male (n = 4)
RBC (·10
6 cells/mL) 10.8 – 0.5 10.8 – 0.5 6.4 – 1.5* 7.2 – 1.8*
HCT (%) 59 – 2.9 62 – 2.7 38 – 8.2* 43 – 10.2*
PLT (·10
3 cells/mL) 1213 – 158 1320 – 167 10 726 – 3987* 6930 – 4840*
WBC (·10
3 cells/mL) 5.3 – 1.8 4.0 – 1.2 81.9 – 39.4* 83.8 – 68.8*
NEUT (cells/mL) 576 – 230 548 – 191 33 764 – 20 917* 34 500 – 29 683*
MONO (cells/mL) 76 – 35 62 – 26 2494 – 1896* 2786 – 2337*
LYM (cells/mL) 4464 – 1697 3067 – 942 40 259 – 16 938* 40 625 – 32 552*
EOS (cells/mL) 127 – 56 89 – 23 918 – 432* 767 – 580*
BASO (cells/mL) 17 – 14 12 – 9.0 337 – 159* 371 – 312*
Data are presented as mean values – SD for animals of 8 weeks of age.
*P < 0.001.
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Moreover, the B-cell-restricted expression of these chimaeras
may have signiﬁcant advantage over conventional transgenic
strategies. The postnatal onset of B-cell development, migra-
tion and directed expression can prevent developmental
effects often seen in transgenic lines. One might presume
that genomic lesions that can arise in cultured ES cells
could result in phenotypes unrelated to transgene expression,
especially when the tissues in the chimaeras are derived
completely from the ES cells. In this regard, the B-cell com-
plementation system, in which only B-lymphocytes are
derived from the injected ES cells, is ‘moderate’ when com-
pared with other complementation systems [tetraploid (20);
RAG-2 (17)]. In addition, producing the chimaeras from mul-
tiple independent, karyotypically normal ES clones may also
be helpful to avoid the confusion in identifying and charac-
terizing subtle phenotypic changes. The following are possible
limitations ofour system,which relies on B-cell-speciﬁc trans-
gene expression. First, the blood–brain barrier should prevent
most circulating transgene products from penetrating the
brain. This may cause difﬁculties in functional evaluation
of transgenes in the central nervous system. Second, some
proteins that require processing by cell-type-speciﬁc
enzyme(s) to generate active forms may not be amenable to
B-cell expression.
The introduction of a single-copy transgene into a prede-
termined site can overcome problems associated with integ-
ration of variable copy numbers of transgenes into random
genomic loci (7). Although the rate of homologous recomb-
ination in mouse ES cells could be an impediment to the
application of this strategy, there are now several approaches
for efﬁcient isolationofES clones carrying the transgene atthe
chosen sites either by site-speciﬁc recombination (21) or by
direct selection of transgene insertion into the Hprt locus (7).
In the present study, we found a greatly improved TR ratio at
the Igk locus in the DRS-ES cell line, which allows for the
efﬁcient isolationof homologous recombinant ES clones using
a standard positive–negative selection vector. Although this
feature of the DRS-ES cell line should beneﬁt our procedure,
further investigations will be required to unravel the molecular
basis for this phenomenon.
As expected, expression studies of our transgenic system
indicate that the transgene is expressed mainly in B-
lymphocytes, which may rely on the transcriptional regulation
from the Igk promoter under the control of surrounding cis-
acting elements. This is supported by successful production
of hybridomas secreting the mTPO protein using splenocytes
prepared from mTPO/WT chimaeras (data not shown).
Although B-cell precursors have been identiﬁed in developing
fetalliverasearlyasday12offetallife,thepopulationshiftfrom
pre-B-cell to a B-cell capable of producing Ig is known to
occur between days 17 and 18 (22). Furthermore, the develop-
ment of various lymphoid organs after birth is accompanied
bydramaticincrease inthe numberofB-cellsand thesynthesis
ofIgs.WethereforesuspectedthattheB-cell-speciﬁctransgene
expression facilitates the analysis of genes whose overexpres-
sion with a strong, constitutive promoter (23) could cause
embryonic lethality. Although the effect of transgene insertion
on the expression of the neighboring endogenous Igk allele
has not been addressed, it may not circumvent the phenotypic
analysis; the serum concentration of total Igs and k/l ratio
were within normal range in transgenic chimaeras (data not
shown).
We observed serum hEPO (5.4 – 1.6 ng/ml, n = 18) and
mTPO (36 – 20 ng/ml, n = 12) protein levels in the chimaeras
(8 weeks of age, Figure 4B) that were elevated compared with
those observed in transgenic animals described previously
[hEPO: 0.1–0.15 ng/ml (6), human TPO:  3 ng/ml (14)].
These results are consistent with the relatively severe pheno-
types observed in the chimaeras. For example, splenomegaly
associated with extramedurally erythropoiesis and doubled
RBC counts were phenotypes described only in a recently
established transgenic with high-level expression of hEPO
( 1.25 ng/ml) (13) and were not commented on in an earlier
report (6).Amonganumberofprevious studiesofdisregulated
TPO production in mice, either by retrovirus (24–26), aden-
ovirus (27,28), repeated TPO injections (29) or transgenesis
(14), only two studies (26,28) reported a large increase in
WBC. Villeval et al. (26) attributed the WBC elevation in
their study to the high-level expression of virally transduced
TPO. It should be noted that, in a traditional transgenic pro-
cedure, at least several lines may generally need to be ana-
lyzedto obtain a single line exhibiting a signiﬁcant level of
transgene expression. We therefore believe that oursystem has
an advantage in terms of speed and efﬁciency in generating
animals that continuously secrete a foreign protein into the
systemic circulation at the levels of tens of nanograms per
milliliter.
As an alternative approach, adenoviral vectors have been
utilizedasvehiclesforinvivogenedelivery.Thelatestversions
ofAdvectorsexhibitimproveddurationoftransgeneexpression
and reduced systemic toxicity (30); however, their efﬁcacy
may depend on the quality of vector preparation and the
route of administration in immuno-competent animals (30).
Inaddition,potentialimmuneresponsesagainsthumanproteins
intransducedanimalscouldcircumventtheeffectiveevaluation
of human genes. The current data have demonstrated the
utility of this procedure as a complementary approach to viral
gene delivery, which should be well suited for studying
chronic, long-term effects of the systemic expression of
human proteins.
Recent technical advances in forward and reverse genetics
in model organisms have facilitated the analysis of in vivo
functions of numerous genes recorded by the Human Genome
Project (31,32). The procedure we described here should be an
important addition to the currently available repertoire of tech-
niques. Systematic and careful phenotypic analysis of trans-
genic chimaeric animals should provide clues to the function
of the newly identiﬁed secreted protein-coding cDNAs, which
may lead to the identiﬁcation of factors that modulate complex
biological processes.
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